Pilot study of the association between the HLA region and testicular carcinoma among Croatian patients.

OBJECTIVES: To analyze the distribution of HLA alleles and HLA microsatellite alleles in Croatian patients with testicular carcinoma, compare it with that of healthy controls and investigate whether the polymorphism within the HLA region could be associated with the development of testicular cancer. METHODS: Genomic DNA was isolated from the peripheral blood of 24 patients with testicular germ cell tumors (TGCT). Patients and controls were typed for HLA class I and class II polymorphism by the PCR-SSO method. Nine HLA microsatellites were analyzed by PCR and electrophoresis in an automated sequencer. RESULTS: No significant deviation in the distribution of frequencies at HLA class I alleles was observed between patients and controls. Among HLA class II alleles, a statistically significant increase in the frequency of the HLA-DPB1*1701 allele was found among patients. The frequency of the HLA-DRB1*07-DQA1*0201-DQB1*0202 haplotype was increased in patients in comparison to the controls. Analysis of HLA microsatellites showed an increased frequency of D6S291-3 allele (p(corr) = 0.0455, OR = 3.05) among patients. CONCLUSIONS: The observed association of the disease and the DPB1*1701 allele as well as with the D6S291-3 allele suggests that this part of the HLA region might be involved in the pathogenesis of TGCT. Our data provide a basis for further studies about the correlation between the HLA region and testicular cancer.

Immunocompetence in non-seminomatous testicular cancer patients before any treatment and one year after completion of therapy.

BACKGROUND: Assessment of immunocompetence in non-seminomatous testicular cancer (NSTC) patients. MATERIALS AND METHODS: In the peripheral blood of 43 patients with NSTC, lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity as well as neutrophil and monocyte phagocytic functions were studied. RESULTS: The proportion and number of T- and B- lymphocytes, lymphocyte reactivity to mitogens as well as neutrophil and monocyte phagocytic functions were equal in patients with localized disease and in those with metastatic disease and they not differ from those in controls. The NK cell number and NK cell activity, however, were significantly impaired in both patient groups. The patients with metastatic disease had a lower NK cell activity than those with localized disease. One year after the completion of anticancer treatment, the NK cell number and cytotoxic activity recovered in both groups of patients. CONCLUSION: These results suggest that patients with NSTC are primarily deficient in NK cell number and their cytotoxic function influence the host's ability to control the proliferation and spread of tumor cells.

Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma.

OBJECTIVE: Assessment of immunocompetence in bladder transitional cell carcinoma (TCC) patients. PATIENTS AND METHODS: In 34 untreated patients with bladder TCC, lymphocyte subsets were measured together with lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions. The data obtained were correlated with both the tumor spread and the grade. RESULTS: In patients with superficial carcinoma, the proportion of CD4+ cells, the reactivity of lymphocytes to mitogens and NK cell activity was significantly lower than in controls. In patients with invasive disease, the CD4/CD8 ratio, lymphocyte reactivity to mitogens and NK cell activity was significantly diminished when compared with the controls and with patients with superficial carcinoma. Neutrophil and monocyte killing was significantly lower than in controls. Patients with high-grade tumors had a significantly lower CD4/CD8 ratio and lymphocyte reactivity to mitogens than patients with low-grade tumors. CONCLUSION: These findings indicate gross immunological abnormalities in TCC patients which correlate with stage and grade of tumor.